GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
Sabrina KatzdoblerGeorg NüblingMartin KlietzUrban M FietzekCarla PalleisAlexander M BernhardtFlorian WegnerMeret HuberSophia RogozinskiLuisa-Sophie SchneiderEike Jakob SpruthAline BeyleIna R VogtMoritz BrandtNiels HansenWenzel GlanzKathrin BrockmannAnnika SpottkeDaniel C HoffmannOliver PetersJosef PrillerJens WiltfangEmrah DüzelAnja SchneiderBjörn FalkenburgerThomas KlockgetherThomas GasserBrigitte NuscherChristian HaassGünter HöglingerJohannes LevinPublished in: Journal of neurology (2024)
In MSA, GFAP shows promise as novel biomarker for assessing current clinical disease severity, while NfL might serve as biomarker for prediction of disease progression and differential diagnosis of MSA against PD.
Keyphrases